{"filings":[{"id":499636,"accession_number":"0001193125-26-228956","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K/A","filed_at":"2026-05-18T20:20:26+00:00","items":["7.01","9.01"],"status":"ready","headline":"Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%","event_type":"other_material","confidence":"high","bullets":["Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.","All evaluable PH-ILD patients improved from Functional Class III to II by Week 24; LAM-001 was generally well tolerated.","Phase 2b trial in PH-ILD to begin mid-2026 with topline data expected in Q1 2028.","8-K/A corrects sign errors in original press release table for PVR percentages (now shown as -35.3% and -33.9% for evaluable population and PH-ILD subgroup respectively).","LAM-001 is an inhaled mTOR inhibitor acquired from Orphai Therapeutics; Quince plans to continue development in PH-ILD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":484436,"accession_number":"0001193125-26-228133","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-05-18T13:33:34+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.","Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.","PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.","Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.","Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94512,"accession_number":"0001193125-26-187243","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).","Still not compliant with Nasdaq market value of listed securities (MVLS) requirement (must be at least $50M); compliance period ends September 14, 2026.","No assurance given that company will meet MVLS requirement or maintain other listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94511,"accession_number":"0001193125-26-170572","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quince Therapeutics appoints June Bray as independent director, expands board to four members","event_type":"leadership","confidence":"high","bullets":["June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.","Bray is deemed independent and will serve on Nominating & Governance, Audit, and Compensation Committees.","Director compensation: $38,000 annual board retainer plus $7,500 (Nominating & Gov), $5,500 (Audit), $4,000 (Comp); no initial option grant.","Bray will enter the company's standard form of indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94510,"accession_number":"0001193125-26-149021","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026","event_type":"other_material","confidence":"high","bullets":["Approximately 16.3M shares outstanding post-split; ratio 1-for-10.","Certificate of Amendment filed with Delaware on April 9; effective 11:59 PM ET April 10.","Split-adjusted trading on Nasdaq begins at market open April 13; new CUSIP 22053A206.","Stock options and warrants proportionally adjusted; no change to rights or preferences.","Equiniti Trust Company appointed as exchange agent; fractional shares paid in cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106948,"accession_number":"0001193125-26-130489","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang","event_type":"debt","confidence":"high","bullets":["Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.","All obligations under the Finance Documents are fully satisfied and discharged.","CEO says settlement removes a substantial constraint on pursuing strategic alternatives.","Company continues restructuring and evaluation of strategic alternatives including M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106947,"accession_number":"0001193125-26-117794","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods","event_type":"other_material","confidence":"high","bullets":["Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.","MVLS Notice: market value of listed securities below $50M for 30 consecutive business days; cure by Sept 14, 2026.","To regain compliance, bid price must close at $1+ for 10 consecutive days, or MVLS at $50M+ for 10 consecutive days.","If not cured by deadline, company may transfer to Nasdaq Capital Market or face delisting.","Stock continues trading on Nasdaq under symbol QNCX during cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106946,"accession_number":"0001193125-26-047544","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger","event_type":"other_material","confidence":"high","bullets":["As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.","Lead drug candidate eDSP failed NEAT trial; no other products; no meaningful operations.","Engaged LifeSci Capital on Feb 9, 2026 to evaluate strategic alternatives including reverse merger.","Common stock closing bid price below $1.00 since Jan 29, 2026; Nasdaq delisting risk.","May need bankruptcy protection if reverse merger fails; Bank has not invoked MAC clause yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106945,"accession_number":"0001193125-26-033758","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Five directors resign from Quince Therapeutics board effective immediately","event_type":"leadership","confidence":"high","bullets":["Directors Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray resigned on Jan 30, 2026.","Resignations were not due to any disagreement with the company on operations, policies, or practices.","CEO Dirk Thye remains as the sole executive officer; no replacements announced.","Company continues under current management; board size reduced from six to one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106944,"accession_number":"0001193125-26-029524","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted","event_type":"other_material","confidence":"high","bullets":["Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.","Key secondary endpoint CGI-S also missed (p=0.522).","eDSP well tolerated; most common adverse events pruritis and pyrexia.","Company to cease clinical development of eDSP and explore available options.","Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123283,"accession_number":"0001193125-25-277523","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.","Phase 3 NEAT enrollment completed (105 participants); topline results expected first quarter 2026.","iDSMB recommended study continue without modifications; 100% of patients chose open-label extension.","Net loss $13.3M ($0.25/sh); R&D expenses $8.1M, G&A expenses $3.3M for Q3 2025.","FDA Fast Track designation; NDA submission planned H2 2026 assuming positive study results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123282,"accession_number":"0001193125-25-242514","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T","event_type":"other_material","confidence":"high","bullets":["Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.","The statement was based on a different study (EJPN Article), not the IntraBio Phase 2 study; Quince removed it from materials.","The EJPN Article found NALL failed to improve motor function significantly but improved some symptoms (e.g., nausea, constipation).","Quince advises investors not to rely on the retracted statement; underlying facts did not support the original claim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139952,"accession_number":"0001193125-25-220722","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026","event_type":"debt","confidence":"high","bullets":["Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.","1% of 9% deferred interest converted to fixed rate, payable March 31, 2026.","Amendment dated September 25, 2025 under EIB Facility originally July 24, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139951,"accession_number":"0000950170-25-106536","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M","event_type":"earnings","confidence":"high","bullets":["Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.","Cash $34.7M; private placement raised ~$11.5M upfront at >10% premium, potential $10.4M from warrants.","Q2 net loss $16.1M ($0.34/shr); R&D $6.6M, G&A $3.3M; cash runway into Q2 2026.","Strategic relationship with Option Care Health (OPCH) to support U.S. commercial launch of eDSP.","New SAB member Dr. Hassan Abolhassani appointed; Phase 2 DMD study design finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139950,"accession_number":"0001193125-25-159886","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026","event_type":"other_material","confidence":"high","bullets":["Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.","Powering at ~90% for primary endpoint; trial under FDA Special Protocol Assessment.","Topline results expected Q1 2026; NDA submission planned H2 2026 if positive.","All enrolled participants have elected to transition to open-label extension study.","FDA Fast Track designation and SPA agreement in place for eDSP in Ataxia-Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157570,"accession_number":"0001193125-25-140873","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Quince raises $11.5M in private placement of stock and warrants; management participates","event_type":"other_material","confidence":"high","bullets":["Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.","Common warrants exercisable at $1.20/share for 5 years; pre-funded warrants exercisable at $0.001/share.","Management investors: CEO Dirk Thye ($200k), COO Brendan Hannah ($50k), President Charles Ryan ($10k).","Company to file resale registration statement within 120 days under Registration Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157569,"accession_number":"0001662774-25-000034","cik":1662774,"company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quince Therapeutics shareholders approve reverse stock split and authorized share increase","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).","Authorized common shares increased from 100M to 250M (27,159,134 for vs 3,776,348 against).","Directors June Bray, Christopher Senner, and Rajiv Patni elected with >85% of votes cast.","BDO USA ratified as independent auditor for FY2025 (30,015,571 for).","Advisory vote on executive compensation passed (16,590,485 for, 800,094 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}